Maze Therapeutics, Inc.
MAZE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $168 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $168 | $0 | $0 |
| % Margin | 100% | – | – |
| R&D Expenses | $83 | $74 | $88 |
| G&A Expenses | $26 | $25 | $23 |
| SG&A Expenses | $26 | $25 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $110 | $99 | $111 |
| Operating Income | $58 | -$99 | -$111 |
| % Margin | 34.4% | – | – |
| Other Income/Exp. Net | -$4 | -$2 | -$4 |
| Pre-Tax Income | $53 | -$100 | -$115 |
| Tax Expense | $1 | $0 | $0 |
| Net Income | $52 | -$100 | -$115 |
| % Margin | 31.2% | – | – |
| EPS | 0.078 | -2.294 | -2.626 |
| % Growth | 103.4% | 12.6% | – |
| EPS Diluted | 0.078 | -2.294 | -2.626 |
| Weighted Avg Shares Out | 44 | 44 | 44 |
| Weighted Avg Shares Out Dil | 44 | 44 | 44 |
| Supplemental Information | – | – | – |
| Interest Income | $5 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $4 |
| EBITDA | $61 | -$94 | -$107 |
| % Margin | 36.3% | – | – |